Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

被引:56
作者
Sagi, Y
Weinstock, M
Youdim, MBH
机构
[1] Technion Fac Med, Ctr Excellence Neurodegenerat Dis Res, Eve Topf & USA Natl Parkinson Fdn, Dept Pharmacol, IL-31096 Haifa, Israel
[2] Hebrew Univ Jerusalem, Sch Med, Dept Pharmacol, IL-91010 Jerusalem, Israel
关键词
dopamine; enzyme inhibition; monoamine oxidase inhibitor; MPTP; neuroprotection; novel cholinesterase; ANTI-ALZHEIMER DRUGS; PARKINSON DRUG; RAT-BRAIN; DISEASE; RASAGILINE; 5-HYDROXYTRYPTAMINE; PREVENTION; DEPRESSION; DEMENTIA; ENZYME;
D O I
10.1046/j.1471-4159.2003.01801.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
(R)-[(N -propargyl-(3R ) aminoindan-5-yl) ethyl methyl carbamate] (TV3326) is a novel cholinesterase and brain-selective monoamine oxidase (MAO)-A/-B inhibitor. It was developed for the treatment of dementia co-morbid with extra pyramidal disorders (parkinsonism), and depression. On chronic treatment in mice it attenuated striatal dopamine depletion induced by MPTP and prevented the reduction in striatal tyrosine hydroxylase activity, like selective B and non-selective MAO inhibitors. TV3326 preferentially inhibits MAO-B in the striatum and hippocampus, and the degree of MAO-B inhibition correlates with the prevention of MPTP-induced dopamine depletion. Complete inhibition of MAO-B is not necessary for full protection from MPTP neurotoxicity. Unlike that seen after treatment with other MAO-A and -B inhibitors, recovery of striatal and hippocampal MAO-A and -B activities from inhibition by TV3326 did not show first-order kinetics. This has been attributed to the generation of a number of metabolites by TV3326 that cause differential inhibition of these enzymes. Inhibition of brain MAO-A and -B by TV3326 resulted in significant elevations of dopamine, noradrenaline and serotonin in the striatum and hippocampus. This may explain its antidepressant-like activity, resembling that of moclobemide in the forced-swim test in rats.
引用
收藏
页码:290 / 297
页数:8
相关论文
共 31 条
[1]  
Barber R, 2001, INT J GERIATR PSYCH, V16, pS12, DOI 10.1002/1099-1166(200112)16:1+<::AID-GPS562>3.0.CO
[2]  
2-3
[3]  
Ben-Shachar D, 1990, J Neural Transm Suppl, V29, P251
[4]   Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders [J].
Binda, C ;
Newton-Vinson, P ;
Hubálek, F ;
Edmondson, DE ;
Mattevi, A .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (01) :22-26
[5]   Influence of culture conditions on monoamine oxidase A and B activity in rat astrocytes [J].
Carlo, P ;
DelRio, M ;
Violani, E ;
Sciaba, L ;
Picotti, GB .
CELL BIOCHEMISTRY AND FUNCTION, 1996, 14 (01) :19-25
[6]  
CORTE L D, 1980, Biochemical Pharmacology, V29, P891, DOI 10.1016/0006-2952(80)90219-1
[7]   MONOAMINE OXIDASE - APPROXIMATION OF TURNOVER RATES [J].
GORIDIS, C ;
NEFF, NH .
JOURNAL OF NEUROCHEMISTRY, 1971, 18 (09) :1673-&
[8]   EFFECTS OF MONOAMINE-OXIDASE INHIBITION BY CLORGYLINE, DEPRENIL OR TRANYLCYPROMINE ON 5-HYDROXYTRYPTAMINE CONCENTRATIONS IN RAT-BRAIN AND HYPERACTIVITY FOLLOWING SUBSEQUENT TRYPTOPHAN ADMINISTRATION [J].
GREEN, AR ;
YOUDIM, MBH .
BRITISH JOURNAL OF PHARMACOLOGY, 1975, 55 (03) :415-422
[9]   EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE A AND TYPE B MONOAMINE-OXIDASE IN RAT-BRAIN INVIVO AND FOR DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5-HYDROXYTRYPTAMINE [J].
GREEN, AR ;
MITCHELL, BD ;
TORDOFF, AFC ;
YOUDIM, MBH .
BRITISH JOURNAL OF PHARMACOLOGY, 1977, 60 (03) :343-349
[10]   PREVENTION OF MPTP-INDUCED NEUROTOXICITY BY AGN-1133 AND AGN-1135, SELECTIVE INHIBITORS OF MONOAMINE OXIDASE-B [J].
HEIKKILA, RE ;
DUVOISIN, RC ;
FINBERG, JPM ;
YOUDIM, MBH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 116 (03) :313-317